Drug Profile
INO 5150
Alternative Names: INO-5150; Prostate cancer DNA vaccine - InovioLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Second-line therapy or greater) in USA (IM)
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Monotherapy, Second-line therapy or greater) in USA (IM)
- 19 Oct 2018 Efficacy and immunogenicity data from phase Ib trial in Prostate cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)